Zymeworks
ZYMEZymeworks is a global biotechnology company focused on the discovery, development, and commercialization of multifunctional biotherapeutics for difficult-to-treat diseases.
Earnings
Next report
Nov 5, 2026 (In 3 weeks)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Zymeworks is a global biotechnology company focused on the discovery, development, and commercialization of multifunctional biotherapeutics for difficult-to-treat diseases. The company leverages proprietary protein engineering and antibody-drug conjugate platforms to build a pipeline of next-generation therapies while employing an asset and royalty aggregation strategy to generate long-term cash flows.
Zymeworks differentiates itself through a dual-track model of internal protein engineering innovation and a disciplined royalty-bearing partnership strategy.
FAQ
- What is Zymeworks's market cap?
- Zymeworks (ZYME) has a market capitalization of $1.8B and trades on NASDAQ.
- What is Zymeworks's revenue and profitability?
- Zymeworks generated $37.1M in trailing twelve-month revenue with a net loss of $150.0M, representing a net margin of -404.0%, with free cash flow of -$120.5M. The latest reported period is Q2 2026.
- Who are Zymeworks's competitors?
- Zymeworks's key competitors include Amgen, Seagen, CDT Equity Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Zymeworks partner with?
- Zymeworks's notable partners include Jazz Pharmaceuticals, BeiGene.
- What subsidiaries does Zymeworks have?
- Zymeworks's subsidiaries include Zymeworks BC Inc..
- Where is Zymeworks headquartered?
- Zymeworks is headquartered in Canada and employs approximately 275 people. It has been publicly traded since 2017.
